€2.54
-0.03 (-1.01%)
EUR · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where DBV.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 2 expanded access · 5 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)NCT07003919DBPC Treatment Period: Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Combination product: DBV712 250 mcg, Placebo | Allergy, Peanut Allergy | 480 | Nov 2026 | ≤ 102 d | 2026-07-22 |
| Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of AgeNCT05741476DBPC Treatment Period: Percentage of Treatment Responders in the DBV712 250 mcg Group Compared to Placebo GroupRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: DBV712, DBV712 · Other: Placebo | Allergy, Peanut | 600 | 2025-11-06actual | — | 2026-01-22 |
| Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young ChildrenNCT03859700Proportion of subjects reaching an ED ≥1000 mgOpen-label · Treatment | Phase 3 | Completed | Biological: DBV712 250 mcg | Peanut Allergy | 304 | 2025-05-13actual | — | 2025-06-06 |
| Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in ChildrenNCT04492683Diagnostic performance of DBV1605Non-randomized · Triple-masked · Diagnostic | Phase 2 | Unknown status | Combination product: DBV1605 | Cow's Milk Allergy | 230 | Mar 2024 | — | 2022-08-11 |
| Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in ChildrenNCT03013517% of subjects originating from the active arm of PEPITES reaching an Eliciting Dose (ED) ≥ 1,000 mg after 24 months of additional treatment in PEOPLEOpen-label · Treatment | Phase 3 | Unknown status | Drug: Viaskin Peanut 250µg | Peanut Allergy | 300 | 2019-11-23actual | — | 2020-12-02 |
| Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of AgeNCT03211247results2024-12-16Percentage of Treatment Responders at Month 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo, Part B Viaskin Peanut 250 mcg, Part B Placebo | Peanut Allergy | 414 | 2019-08-20actual | — | 2024-12-16 |
| A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic SubjectsNCT03352726Biological potency of the In-House Reference peanut proteins extract (DBV712-IHRP) in arbitrary Biological Units (BU)Open-label · Other | Phase 1 | Completed | Drug: DBV712 IHRP | Peanut Allergy | 27 | 2018-06-29actual | — | 2019-07-26 |
| Viaskin Pertussis Vaccine TrialNCT03035370Incidence of Treatment-Emergent Adverse Events (AE).Randomized · Quadruple-masked · Other | Phase 1 | Completed | Biological: Viaskin PT 25 mcg, Viaskin PT 50 mcg, Viaskin PT Placebo, Boostrix™ | Whooping Cough | 102 | 2018-04-25actual | — | 2020-03-02 |
| Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk AllergyNCT02223182results2024-11-20Percentage (%) of Subjects Who Are Treatment Responders After 12 Months of EPIT Treatment.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg, Viaskin Placebo | Food Allergy | 198 | 2017-12-14actual | — | 2024-11-20 |
| Safety Study of Viaskin Peanut to Treat Peanut AllergyNCT02916446Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Biological: Viaskin Peanut 250 mcg, Placebo | Peanut Allergy | 393 | 2017-09-22actual | — | 2021-02-03 |
| Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut AllergyNCT02636699results2021-10-15Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall PopulationRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Viaskin Peanut 250mcg, Placebo | Peanut Allergy | 500 | 2017-08-18actual | — | 2025-06-18 |
| Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and ChildrenNCT01955109results2022-06-30Percentage of Treatment Responders at Months 12 and 24Open-label · Treatment | Phase 2 | Completed | Biological: Viaskin Peanut 250 mcg | Peanut Allergy | 171 | Sep 2016actual | — | 2022-06-30 |
| Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut AllergyNCT01675882results2021-10-27Percentage of Treatment Responders at Month 12; Analyzed in Overall PopulationRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg, Viaskin Placebo | Peanut Allergy | 221 | Jul 2014actual | — | 2021-10-27 |
| Safety of Epicutaneous Immunotherapy for the Treatment of Peanut AllergyNCT01170286Safety evaluationRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: Whole peanut extract, Placebo formulation | Peanut Allergy | 100 | Feb 2012actual | — | 2012-03-23 |
| Viaskin® Peanut (DBV712) Expanded Access ProtocolNCT04371627expanded access | — | No longer available | Drug: Viaskin Peanut | Peanut Allergy | — | — | — | 2021-05-28 |
| Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic ChildrenNCT05424731expanded access | — | Available | Combination product: DBV712 250 mcg | Peanut Allergy | — | — | — | 2026-01-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19